IGC Reveals 2024 Annual Stockholders Meeting Results

IGC Pharma, Inc. (IGC), a biotechnology company focusing on innovative treatments for Alzheimer's disease, announced that all proposals presented at its Annual Meeting of Stockholders on August 23, 2023, were approved. Only stockholders on record as of June 28, 2024, participated in the voting.

During the meeting, several key decisions were made. Firstly, the stockholders voted to re-elect Mr. Richard Prins and Mr. Terry Lierman as Class B directors on the company's board. They will serve until the 2027 annual meeting. Secondly, stockholders ratified the appointment of Manohar Chowdhry & Associates as the independent registered public accounting firm for the fiscal year of 2025. Lastly, the proposal to grant 5,000,000 shares of common stock to current and new employees, advisors, directors, and consultants was approved. These shares will be distributed based on performance, vesting, and incentives as determined by the board of directors or the CEO.

IGC Pharma is a clinical-stage biotechnology company that leverages AI technology to develop treatments for Alzheimer's disease. The company's portfolio includes various therapeutic candidates targeting different aspects of the disease. One notable candidate is TGR-63, which aims to address amyloid plaques, a significant feature of Alzheimer's. Additionally, IGC is advancing its IGC-C and IGC-M platforms through preclinical studies. These platforms focus on several disease markers such as metabolic disorders, tau proteins, and early plaque formation.

The company's leading therapeutic candidate, IGC-AD1, is currently in a Phase 2 clinical trial. This cannabinoid-based treatment is designed to manage agitation in dementia patients associated with Alzheimer's disease. Interim data from the trial suggests that IGC-AD1 may offer quicker relief and be more effective than traditional medications.

Beyond developing therapeutic solutions, IGC Pharma is utilizing AI to enhance its research and development efforts. The company's AI models are employed to predict biomarkers for early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among other tasks. To date, IGC Pharma has filed 28 patents, underscoring its commitment to innovation and the advancement of pharmaceutical treatments.

IGC Pharma continues to make strides in the field of biotechnology with a strong focus on improving the lives of those affected by Alzheimer's and related conditions. The company's innovative approach and dedication to research are pivotal in its mission to develop effective and safe treatments for this debilitating disease.